Pirfenidone for the treatment of idiopathic pulmonary fibrosis

Expert Review of Clinical Pharmacology

Volumn 10, Issue 5, 2017, Pages 483-491

  George, Peter M ^a   Wells, Athol U ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

ASCEND study; CAPACITY study; clinical end points; idiopathic pulmonary fibrosis; ILD; Interstitial lung disease; IPF; lung function; nintedanib; pirfenidone

Indexed keywords

PIRFENIDONE; INDOLE DERIVATIVE; NINTEDANIB; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; DECREASED APPETITE; DRUG ABSORPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; REVIEW; VOMITING; ANIMAL; BIOASSAY; DISEASE COURSE; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85014567984     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1295846     Document Type: Review

References (80)

1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement:update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748.
2. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older:incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566–572.
3. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–985.
4. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199–203.
5. Nicholson AG, Colby TV, Du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213–2217.
6. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
7. Spagnolo P, Maher TM, Richeldi L., Idiopathic pulmonary fibrosis:recent advances on pharmacological therapy. Pharmacol Ther. 2015;152:18–27.
8. Raghu G, Anstrom KJ, King TE, et al.; Network IPFCR. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.•• The PANTHER trial was crucial in dispelling the concept that immunosupression is a useful treatment for IPF. This trial demonstrated quite the converse; that immunosupression in this patient group has the potential to cause harm.
9. Gadekar S, 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use. US patent 3,974,281; 1976. 143 741–758
10. Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125(6):779–785.• One of the first publications demonstrating the potential of Pirfenidone to have antifibrotic properties using a murine model of pulmonary fibrosis.
11. Iyer SN, Margolin SB, Hyde DM, et al. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 1998;24(1):119–132.
12. Maher TM, Wells AU, Laurent GJ., Idiopathic pulmonary fibrosis:multiple causes and multiple mechanisms? Eur Respir J. 2007;30(5):835–839.
13. Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002;446(1–3):177–185.
14. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther. 2003;16(4):207–214.
15. Visner GA, Liu F, Bizargity P, et al. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation. 2009;88(3):330–338.
16. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446(1–3):167–176.
17. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone:different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–408.
18. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000;24(5):477–491.
19. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276(2 Pt 1):L311–8.
20. Iyer S, Du X, Norris C, et al. Effects of pirfenidone on inflammatory and anti-inflammatory cytokines, CD4 and CD8 T-cells and nitric oxide levels in bronchoalveolar lavage fluid in bleomycin-mouse model of pulmonary fibrosis. Am J Respir Crit Care Med. 2003;167:A621.
21. Giri SN, Leonard S, Shi X, et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol. 1999;18(3):169–177.
22. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol. 1998;113(1):72–76.
23. Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19.
24. Lee BS, Margolin SB, Nowak RA. Pirfenidone:a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998;83(1):219–223.
25. Zhang S, Shiels IA, Ambler JS, et al. Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol. 1998;26(Suppl 1):S74–6.
26. Fernandez IE, Eickelberg O. The impact of TGF-β on lung fibrosis:from targeting to biomarkers. Proc Am Thorac Soc. 2012;9(3):111–116.
27. Jagirdar J, Begin R, Dufresne A, et al. Transforming growth factor-beta (TGF-beta) in silicosis. Am J Respir Crit Care Med. 1996;154(4 Pt 1):1076–1081.
28. Maeda A, Ishioka S, Taooka Y, et al. Expression of transforming growth factor-beta1 and tumour necrosis factor-alpha in bronchoalveolar lavage cells in murine pulmonary fibrosis after intraperitoneal administration of bleomycin. Respirology. 1999;4(4):359–363.
29. Kwong KY, Literat A, Zhu NL, et al. Expression of transforming growth factor beta (TGF-beta1) in human epithelial alveolar cells:a pro-inflammatory mediator independent pathway. Life Sci. 2004;74(24):2941–2957.
30. Kitamura H, Cambier S, Somanath S, et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest. 2011;121(7):2863–2875.
31. Card JW, Racz WJ, Brien JF, et al. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci. 2003;75(1):169–180.
32. Keerthisingam CB, Jenkins RG, Harrison NK, et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 2001;158(4):1411–1422.
33. Togami K, Kanehira Y, Tada H. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Biol Pharm Bull. 2013;36(10):1525–1527.
34. Hisatomi K, Mukae H, Sakamoto N, et al. Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med. 2012;12:24.
35. Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett. 1997;90(2–3):125–132.
36. Zhou H, Latham CW, Zander DS, et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant. 2005;24(10):1577–1585.
37. Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycin. Chin Med Sci J. 2006;21(3):145–151.
38. Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J. 2004;24(1):57–65.
39. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem. 2000;204(1–2):119–126.
40. Di Sario A, Bendia E, Svegliati Baroni G, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002;37(5):584–591.
41. García L, Hernández I, Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. 2002;37(6):797–805.
42. Hewitson TD, Kelynack KJ, Tait MG, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol. 2001;14(6):453–460.
43. Wang J, Yang Y, Xu J, et al. Pirfenidone inhibits migration, differentiation, and proliferation of human retinal pigment epithelial cells in vitro. Mol Vis. 2013;19:2626–2635.
44. Tampe D, Zeisberg M. Potential approaches to reverse or repair renal fibrosis. Nat Rev Nephrol. 2014;10(4):226–237.
45. RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol. 2009;20(8):1765–1775.
46. Takakura K, Mizukami K, Mitori H, et al. Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis. Eur J Pharmacol. 2014;737:106–116.
47. Nguyen DT, Ding C, Wilson E, et al. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm. 2010;7(10):1438–1445.
48. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20(120):85–97.
49. Wang Y, Wu Y, Chen J, et al. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013;126(1):1–11.
50. Leask A. Getting to the heart of the matter:new insights into cardiac fibrosis. Circ Res. 2015;116(7):1269–1276.
51. Yamagami K, Oka T, Wang Q, et al. Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts. Am J Physiol Heart Circ Physiol. 2015;309(3):H512–22.
52. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–285.
53. Togami K, Kanehira Y, Tada H. Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapy. Biopharm Drug Dispos. 2015;36(4):205–215.
54. Shi S, Wu J, Chen H, et al. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007;47(10):1268–1276.
55. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone:results of a prospective, open-label phase II study. Am J Respir Crit Care Med. 1999 Apr; 159 (4 Pt 1):1061–1069.•• This seminal clinical study was the first to demonstrate the antifibrotic effect of Pirfenidone in patients with IPF.
56. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–1047.• The first randomised controlled trial of Pirfidone in IPF led to Japan being the first country to grant the licence for the use of pirfenidone in 2008.
57. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829.
58. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):two randomised trials. Lancet. 2011;377(9779):1760–1769.•• Phase III Clinical trials - the CAPACITY studies (004 and 006) demonstrating efficacy of Pirfenidone in the treatment of IPF. However there was some disparity between the two trials leading to a call for a final trial - the ASCEND trial.
59. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011;377(9779):1727–1729.
60. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.•• Phase III Clinical trial - ASCEND Study confirming efficacy of Pirfenidone in the treatment of IPF.
61. Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis:considerations for future clinical trials. Eur Respir J. 2015;46(1):243–249.
62. Wells AU, Behr J, Costabel U, et al. Hot of the breath:mortality as a primary end-point in IPF treatment trials:the best is the enemy of the good. Thorax. 2012;67(11):938–940.
63. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis:clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044–1048.
64. Ryerson CJ. Risk prediction and end-points in idiopathic pulmonary fibrosis:one step at a time. Eur Respir J. 2014;43(5):1237–1239.
65. Saville BR, Herring AH, Koch GG. A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data. Stat Med. 2010;29(1):75–85.
66. Saville BR, Koch GG. Estimating covariate-adjusted log hazard ratios in randomized clinical trials using cox proportional hazards models and nonparametric randomization based analysis of covariance. J Biopharm Stat. 2013;23(2):477–490.
67. Vancheri C, Du Bois RM., A progression-free end-point for idiopathic pulmonary fibrosis trials:lessons from cancer. Eur Respir J. 2013;41(2):262–269.
68. Pocock SJ, Ariti CA, Collier TJ, et al. The win ratio:a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33(2):176–182.
69. Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity:analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71(5):429–435.
70. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis:analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253.
71. Lancaster L, Albera C, Bradford WZ, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis:integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016;3(1):e000105.
72. Koschel D, Cottin V, Skold M, et al. Pirfenidone post-authorisation safety registry (PASSPORT)–interim analysis of IPF treatment. Eur Respir J. 2014;44:(Suppl. 58):1904.
73. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–391.
74. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58–64.
75. Chaudhuri N, Duck A, Frank R, et al. Real world experiences:pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224–226.
76. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis:real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration. 2014;88(3):199–207.
77. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(5):740–747.
78. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP:an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(3):198–205.
79. Wells A. Combination therapy in idiopathic pulmonary fibrosis:the way ahead will be hard. Eur Respir J. 2015;45(5):1208–1210.
80. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy:the future of management for idiopathic pulmonary fibrosis?. Lancet Respir Med. 2014;2(11):933–942.